King Tuber Mushroom

Metadata

Regulatory Status

Nigeria and West Africa

• Traditional medicine status: The sclerotium of P. tuber-regium is widely used in Nigerian traditional medicine, known as “Osu” in the Igbo language. Traditional practitioners use it to treat headaches, stomach ailments, colds, constipation, fever, asthma, smallpox, nervous disorders, and high blood pressure.
• Food status: The sclerotium is popularly consumed in Nigeria as a food and culinary ingredient. It is lifted from soil or wood and processed for use in soups and stews.
• Economic importance: P. tuber-regium has significant economic importance across West and Central Africa, where both the sclerotium and fruiting body are traded in local markets.
• Cultivation: Successfully cultivated in Nigeria and other West African countries, though much of the supply still comes from wild harvest.

China

• Traditional use: Used in traditional Chinese medicine for various ailments. Cultivated commercially in some Chinese provinces.
• Research base: Chinese researchers have contributed significantly to the pharmacological characterization of P. tuber-regium, particularly its polysaccharide chemistry and antidiabetic properties.
• Not pharmacopoeial: Not listed in the Chinese Pharmacopoeia.

United States

• Status: Not commercially available as a food or supplement. No FDA GRAS determination. Not marketed under DSHEA.

European Union

• Status: Not commonly available in European markets. No novel food authorization for extracts or supplements.

Conditions & Indications

Primary Indications (Preclinical and Ethnopharmacological Evidence)

• Antitumor activity — Hot water extracts of both mycelia and sclerotia demonstrated strong in vitro and in vivo antitumor activities against HL-60 tumor cell culture and Sarcoma 180 solid tumors in BALB/c mice. Nonstarch polysaccharide fractions (dietary fiber) from sclerotia, administered intraperitoneally at 20 mg/kg body weight, inhibited Sarcoma 180 proliferation with an inhibition ratio of 50% or greater. Two fractions outperformed 5-fluorouracil in tumor weight reduction. Carboxymethylated beta-glucans from sclerotia showed enhanced antitumor activity correlated with increased water solubility and extended molecular chain conformation.
• Antidiabetic activity — Sclerotial polysaccharides attenuated hyperglycemia and oxidative stress in streptozotocin-induced diabetic rats. Blood glucose levels decreased significantly in polysaccharide-treated groups, with decreased glycated hemoglobin (HbA1c) paralleling glucose reduction. Protection of pancreatic beta-cells by polysaccharides was proposed as a key mechanism of antidiabetic activity.

Secondary Indications (Preclinical and Ethnopharmacological Evidence)

• Immunomodulation and immunorestoration — Beta-D-glucan-rich extract and polysaccharide fractions demonstrated both immunomodulatory and immunorestorative activities, enhancing immune cell function and restoring suppressed immune responses. These findings support the traditional use of sclerotium preparations for immune support.
• Hypocholesterolemic activity — Dietary supplementation with P. tuber-regium ameliorated dyslipidemia in obese type 2 diabetic rats, reducing total cholesterol and LDL cholesterol while modifying the lipid profile toward a less atherogenic pattern. The sclerotium’s high beta-glucan content is believed to mediate cholesterol-binding and bile acid sequestration in the gut.
• Anti-inflammatory activity — Mycelia and bioactive constituents inhibited lipopolysaccharide (LPS)-induced inflammatory responses in RAW 264.7 macrophages, reducing production of pro-inflammatory mediators.
• Antihypertensive effects — Used traditionally for high blood pressure in Nigerian folk medicine; some preclinical evidence supports blood pressure reduction, though specific mechanistic studies are limited.

Emerging/Preclinical Indications

• Mineral absorption enhancement — Colonic fermentation of sclerotial beta-glucans enhanced the absorption of calcium and magnesium in ovariectomized rats, suggesting potential application in osteoporosis prevention.
• Antigenotoxic activity — Demonstrated protective effects against DNA damage in certain experimental systems.
• Antioxidant activity — Polysaccharides from both sclerotia and fruiting bodies showed significant in vitro antioxidant activity including DPPH, hydroxyl radical, and superoxide anion scavenging.

Mechanism of Action

Primary Mechanisms

1. Beta-glucan-mediated antitumor immunity The sclerotium of P. tuber-regium is extraordinarily rich in beta-1,3-D-glucan, with glucose constituting approximately 90% of the dietary fiber fraction and glucosamine (from chitin) making up approximately 6%. These beta-glucans activate innate immune cells — macrophages, natural killer cells, and dendritic cells — through pattern recognition receptors, principally Dectin-1. The resulting immune activation includes enhanced phagocytosis, increased cytokine production, and augmented NK cell cytotoxicity directed against tumor cells. The antitumor effect is therefore host-mediated rather than directly cytotoxic. Carboxymethylation of the beta-glucan chain increases water solubility and extends the molecular chain conformation, which correlates with enhanced antitumor activity — likely due to improved bioavailability and enhanced receptor engagement.

2. Pancreatic beta-cell protection in diabetes Sclerotial polysaccharides protect pancreatic beta-cells in streptozotocin-induced diabetic models. The mechanism involves reduction of oxidative stress (decreased lipid peroxidation markers, increased antioxidant enzyme activity) that would otherwise damage insulin-producing cells. By preserving beta-cell mass and function, the polysaccharides maintain insulin secretory capacity and thereby reduce hyperglycemia. The parallel reduction in HbA1c confirms sustained glycemic control rather than transient glucose-lowering effects.

3. Cholesterol metabolism through bile acid sequestration The high beta-glucan and dietary fiber content of sclerotial preparations binds bile acids in the intestinal lumen, interrupting enterohepatic circulation and promoting fecal bile acid excretion. This forces the liver to convert additional cholesterol to bile acids via CYP7A1, reducing hepatic and circulating cholesterol levels. This mechanism is analogous to the cholesterol-lowering effect of oat beta-glucan, which is well-established in human nutrition.

Secondary Mechanisms

• Anti-inflammatory NF-kB pathway modulation: Bioactive constituents from P. tuber-regium mycelia suppress LPS-induced inflammatory responses in macrophages, likely through inhibition of NF-kB signaling and reduction of iNOS expression and pro-inflammatory cytokine production.
• Immunorestorative activity: Beyond immunostimulation, P. tuber-regium polysaccharides demonstrate the ability to restore suppressed immune function, distinguishing them from purely stimulatory agents. This dual modulation (stimulating when immune function is low, potentially regulating when it is overactive) has been described in the beta-glucan literature for several species.
• Prebiotic fermentation: Sclerotial polysaccharides that resist upper gastrointestinal digestion serve as fermentation substrates for colonic microbiota, promoting short-chain fatty acid (SCFA) production and enhancing mineral absorption (calcium, magnesium) through colonic acidification.

Key Active Compounds

Clinical Evidence Summary

No human clinical trials have been conducted with Pleurotus tuber-regium. The evidence base consists entirely of preclinical studies and ethnopharmacological documentation.

Key Preclinical Studies

Evidence Limitations

• No human clinical trials exist for any therapeutic indication.
• Most antitumor studies used transplanted tumor models (Sarcoma 180, HL-60) with limited translational relevance.
• Antidiabetic evidence comes from the streptozotocin-induced diabetic rat model, which models type 1 diabetes rather than the more common type 2 diabetes.
• The traditional medicine uses documented in ethnopharmacological surveys have not been validated through controlled clinical studies.
• Dose-response relationships for human use have not been established.
• The sclerotium varies in composition depending on substrate, growing conditions, and maturity, complicating standardization.
• Long-term safety data beyond traditional food consumption patterns are lacking.
• Carboxymethylated beta-glucan derivatives, while promising, are chemically modified products that differ from the native compounds consumed traditionally.

Safety Profile

General Assessment

P. tuber-regium sclerotia and fruiting bodies have been consumed as food in West Africa and parts of Asia for centuries with no documented adverse effects. The sclerotium is particularly valued as a nutritious food that is high in beta-glucan fiber and low in crude lipid content. Comprehensive reviews of the species’ toxicity profile have confirmed safety at studied doses in animal models.

Contraindications

• Known mushroom allergy: Individuals with allergies to Pleurotus species or other basidiomycete mushrooms should avoid P. tuber-regium.
• Pregnancy and lactation: Culinary consumption is likely safe based on long traditional use. Concentrated extracts or supplement doses should be avoided due to insufficient specific safety data.

Drug Interactions

• Potential — antidiabetic agents: Given demonstrated blood glucose-lowering effects in diabetic animal models, concurrent use of concentrated P. tuber-regium extracts with insulin or oral hypoglycemic agents could theoretically increase hypoglycemia risk. No clinical interaction studies exist.
• Potential — statins and lipid-lowering drugs: Hypocholesterolemic effects documented in animal models suggest possible additive effects with prescribed lipid-lowering medications.
• Potential — immunosuppressants: Immunomodulatory and immunorestorative properties suggest potential interference with immunosuppressive therapy.
• Potential — anticoagulants: No specific data, but general caution is warranted with concentrated mushroom polysaccharide preparations in patients on anticoagulant therapy.

Side Effects

• From food consumption: No adverse effects documented from traditional dietary use.
• From extracts in animal studies: No significant toxicity reported at tested doses.
• General considerations: High beta-glucan fiber content may cause gastrointestinal effects (bloating, flatulence) in individuals not accustomed to high-fiber diets, particularly with sclerotial preparations.

Clinical Dosage

Traditional Use (West African)

• Sclerotium: Traditionally prepared by drying, grinding into powder, and incorporating into soups, stews, or medicinal preparations. The sclerotium is typically harvested from soil or decaying wood where it can grow to the size of a fist or larger (5-30 cm diameter).
• Dosage in traditional practice: Not standardized; consumed as a food and medicine component according to traditional practitioner guidance.

As Culinary Food

• Fresh fruiting body: Edible and consumed in the same manner as other oyster mushrooms. The fruiting bodies emerge from the sclerotium and are typical Pleurotus-type mushrooms.
• Dried sclerotium powder: Used as a thickener and nutritional supplement in West African cuisine, particularly in soups.

Extrapolated from Animal Studies (No Human Validation)

• Polysaccharide fractions (antitumor): 20 mg/kg body weight (i.p.) in mice. No human oral dose established.
• Polysaccharide fractions (antidiabetic): Various doses used in rat studies. Human-equivalent doses have not been calculated.
• Dietary supplementation: 5-10% of diet as sclerotium powder in animal studies.

Preparation Notes

• The sclerotium is the most distinctive feature of P. tuber-regium and the primary medicinal part. It is a dense, compact mass of fungal tissue that serves as a nutrient and water storage organ, enabling the fungus to survive adverse environmental conditions.
• Hot water extraction is the standard method for isolating bioactive polysaccharides from the sclerotium.
• Carboxymethylation of sclerotial beta-glucans produces water-soluble derivatives with enhanced biological activity, though this is a laboratory process not applicable to traditional preparation.

Sources

• Huang HY, Korivi M, Chaing YY, et al. Pleurotus tuber-regium polysaccharides attenuate hyperglycemia and oxidative stress in experimental diabetic rats. Evid Based Complement Alternat Med. 2012;2012:856381
• Ooi VE. Evaluation of mushroom dietary fiber (nonstarch polysaccharides) from sclerotia of Pleurotus tuber-regium (Fries) Singer as a potential antitumor agent. J Agric Food Chem. 2001;49(12):6005-6009
• Zhang M, Cheung PC, Zhang L. Molecular mass and chain conformation of carboxymethylated derivatives of beta-glucan from sclerotia of Pleurotus tuber-regium. Biopolymers. 2003;68(2):157-163
• Tao Y, et al. Chemical modification and antitumor activities of two polysaccharide-protein complexes from Pleurotus tuber-regium. Int J Biol Macromol. 2009;44(2):109-115
• Adejoye OD, et al. Immunomodulatory and immunorestorative activities of beta-d-glucan-rich extract and polysaccharide fraction of mushroom, Pleurotus tuber-regium. Pharm Biol. 2015;53(11):1555-1566
• Huang HY, Huang ML. Inhibitory effects of Pleurotus tuber-regium mycelia and bioactive constituents on LPS-treated RAW 264.7 cells. J Funct Foods. 2013;5(4):1560-1567
• Adeniran HA, et al. Pleurotus tuber-regium inclusion in diet ameliorates dyslipidaemia in obese-type 2 diabetic rats. Clin Phytosci. 2021;7:92
• Wong KH, et al. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol. 2006;40(3):235-243
• Agu KC, et al. The King Tuber Medicinal Mushroom Pleurotus tuber-regium (Agaricomycetes): A Review on Nutritional Composition, Phytochemistry, Pharmacological Activities, and Toxicity Profile. Int J Med Mushrooms. 2022;24(8):1-18
• Okhuoya JA, et al. Development of high yielding strain of Pleurotus tuber-regium: fructification, nutritional and phylogenetic studies. Mycology. 2019;10(3):135-144
• Tes T. Analysis of the Bioactive Nutrients and Pharmacologically Active Substances in Pleurotus tuber-regium. Trop Environ Stud. 2022;29

Connections

• Oyster Mushroom — The common oyster mushroom (P. ostreatus) is the most widely known member of the Pleurotus genus. P. tuber-regium is unique among Pleurotus species in forming a large underground sclerotium, which distinguishes its medicinal application from all other oyster mushroom species.
• King Trumpet — Another Pleurotus species with significant culinary and medicinal value, but lacking sclerotium formation. Both share general Pleurotus polysaccharide immunomodulatory properties.
• Poria — Wolfiporia extensa (Poria cocos) also forms a large underground sclerotium used in TCM. The sclerotia of both species are rich in beta-glucans and share similar pharmacological profiles (antitumor, immunomodulatory, diuretic). P. tuber-regium and Poria represent convergent evolution of the sclerotium-forming strategy in unrelated fungal lineages.
• Maitake — Both species demonstrate potent beta-glucan-mediated antitumor activity. Maitake D-fraction provides a well-studied comparator for P. tuber-regium antitumor polysaccharides. Potential synergy through activation of complementary immune pathways.
• Turkey Tail — PSK and PSP from turkey tail represent the gold standard for mushroom-derived antitumor polysaccharide therapeutics, providing context for the potential clinical development of P. tuber-regium carboxymethylated beta-glucans.
• Lung Oyster — A close Pleurotus relative with immunomodulatory properties but lacking sclerotium formation.
• Reishi — As the most thoroughly studied immunomodulatory mushroom, reishi provides the pharmacological framework for understanding P. tuber-regium’s immune-enhancing properties.